Navigation Links
Genzyme Announces Presentation of New Positive Data on Carticel(R)
Date:3/10/2008

st cell therapy to be approved by the FDA. First introduced in March of 1995, Carticel received accelerated approval from the FDA in August of 1997 after the FDA instituted specific cell therapy guidelines. Under accelerated approval, the FDA required Genzyme to conduct confirmatory post-marketing clinical studies. Genzyme successfully completed the confirmatory studies and, in June of 2007, the FDA deemed the commitment satisfied.

To learn more about Carticel please visit http://www.carticel.com.

Cell Therapy Expertise at Genzyme

Genzyme has more than a decade of experience in developing and manufacturing autologous cell therapy products that have been used to treat thousands of patients. Epicel(R) (cultured epidermal autografts), a cell therapy for treating patients with severe burns, is also manufactured by Genzyme. Together, Carticel and Epicel represent the first such products ever brought to market in the United States, providing Genzyme with superior scientific and commercial expertise in this field.

About Carticel

CARTICEL is for autologous use and is indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure (e.g., debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft). CARTICEL should only be used in conjunction with debridement, placement of a periosteal flap and rehabilitation. The independent contributions of the autologous cultured chondrocytes and other components of the therapy to outcome are unknown. It is not indicated for the treatment of cartilage damage associated with generalized osteoarthritis. It is not recommended for patients whose knee meniscus has been surgically removed unless the patient has undergone surgical reco
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
4. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014  IGI Laboratories, Inc. (NYSE MKT: ... of its offering of $125 million aggregate principal amount ... The Notes were offered and sold only to qualified ... Act of 1933, as amended (the "Securities Act"). ... of 3.75% per year, payable semiannually in arrears on ...
(Date:12/17/2014)... PCCA received the Autism Hope Alliance,s ... program seal for best practices in meeting needs ... practices, materials and goods that meet strict criteria ... affected by autism often have unique physical or ... found in food and medicine – for instance ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Electrocardiogram (ECG) Devices - Global Trends, Estimates ... http://photos.prnewswire.com/prnh/20130307/600769 Global ... million by 2016. The North America ... market share while Europe claims ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... biotechnology,company Crucell N.V., the Aeras Global TB Vaccine ... present a progress update,and immunology data from a ... "Tuberculosis Vaccines for the World" conference (Atlanta,Georgia, April ... Worcester, South,Africa and launched in May 2007, is ...
... Officer, to present interim results of the ... Injury, HOPKINTON, Mass., April 9, 2008 Alseres,Pharmaceuticals, ... 15, 2008, Dr.,Mark Hurtt, Chief Medical Officer, will discuss ... panel on Spinal Cord Injury Research,during a congressional briefing ...
Cached Medicine Technology:Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 2Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 3Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 4Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 5Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 6Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008 2Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008 3Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... private insurance could boost the ranks of the uninsured , , ... going without health insurance for a period of time is ... survey has found. , These gaps in coverage, however, are ... insurance through public programs, such as Medicaid. , "The bad ...
... (Nasdaq: NUVA ), a medical device company ... for the spine, announced today that it has agreed ... focused on clinical approval of the PCM(R) cervical disc ... strategic acquisition allows NuVasive the potential to accelerate its ...
... ResMed Inc. (NYSE: RMD ), announced today ... results for the third quarter and nine months of fiscal ... ResMed,s results will be issued after 1:00 p.m. Pacific Time ... to review its results, market trends, and future outlook.The conference ...
... mean a 10% decline in information recall, scientists say, ... teens go on a binge drinking episode, they may ... in their brain, a new MRI-based study suggests. , ... cells, the researchers said. This means that damage caused ...
... -- Revenues of $73.8 million, -- Gross ... of $12.8 million or $0.27 per diluted share, , ... "Lotus" or the,"Company") today reported its strong 2008 results with ... total net revenues; gross profit,increasing to $33.4 million, up 44% ...
... Ethicon Endo-Surgery today announced the ... are featured in 15 studies being presented at ... Surgeons (SAGES) Annual Meeting. Setting the stage for ... preliminary experiences with the devices during, or with ...
Cached Medicine News:Health News:More Americans Experiencing Gaps in Health Coverage 2Health News:More Americans Experiencing Gaps in Health Coverage 3Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 2Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 3Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 4Health News:ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2009 Results 2Health News:Binge Drinking May Damage Teens' Brains 2Health News:Binge Drinking May Damage Teens' Brains 3Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 2Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 3Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 4Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 5Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 6Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 7Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 8Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 9Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 10Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 11Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 12Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 13Health News:Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages 2Health News:Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages 3Health News:Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages 4
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... Arthrotek® Precision Hand Instruments were developed ... tactile feel, while still having an instrument ... spaces without the fear of the bending ... designed and manufactured to conform to the ...
Medicine Products: